Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM.

Clin Cancer Res. 2011 Aug 1;17(15):5113-22. doi: 10.1158/1078-0432.CCR-11-0237. Epub 2011 Jun 20.

2.

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ.

Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71. doi: 10.1007/s00280-009-1170-y. Epub 2009 Dec 5. Review.

PMID:
19967539
3.
4.

Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.

Funakoshi T, Latif A, Galsky MD.

Cancer Treat Rev. 2013 Nov;39(7):818-30. doi: 10.1016/j.ctrv.2013.01.004. Epub 2013 Feb 28. Review.

PMID:
23455076
5.

Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.

Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey S, London AJ, Kimmelman J.

J Natl Cancer Inst. 2015 Nov 7;108(1). pii: djv292. doi: 10.1093/jnci/djv292. Print 2016 Jan. Review.

6.

Developmental therapeutics in childhood cancer. A perspective from the Children's Oncology Group and the US Food and Drug Administration.

Bernstein ML, Reaman GH, Hirschfeld S.

Hematol Oncol Clin North Am. 2001 Aug;15(4):631-55. Review.

PMID:
11676277

Supplemental Content

Support Center